SCHEMBL14988368

SCHEMBL14988368

Nc1c(N=Nc2ccc(-c3ccccc3)nc2)cc(S(=O)(=O)O)c2ccccc12.[NaH]

nearest known ligand 0.77

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.67
▸ ALDH1A1 P00352 1/20 0.67
▸ APP P05067 1/20 0.67
▸ MAPT P10636 1/20 0.67
▸ THRB P10828 1/20 0.67
▸ HPGD P15428 1/20 0.67
▸ ALOX12 P18054 1/20 0.67
▸ SNCA P37840 1/20 0.67
▸ RECQL P46063 1/20 0.67
▸ BLM P54132 1/20 0.67
▸ KMT2A Q03164 1/20 0.67
▸ TDP1 Q9NUW8 1/20 0.67
▸ SUMO2 P61956 1/20 0.67
▸ SUMO1 P63165 1/20 0.67
▸ SENP7 Q9BQF6 1/20 0.67
▸ SENP2 Q9HC62 1/20 0.67
▸ SENP1 Q9P0U3 1/20 0.67
▸ SLC7A11 Q9UPY5 3/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14988362 1.00 MEN1 (0.67) MEN1ALDH1A1APPMAPTTHRB
SCHEMBL18044221 0.99 MEN1 (0.69) MEN1ALDH1A1APPMAPTTHRB
SCHEMBL15120143 0.99 MEN1 (0.69) MEN1ALDH1A1APPMAPTTHRB
SCHEMBL29697208 0.99 MEN1 (0.69) MEN1ALDH1A1APPMAPTTHRB
SCHEMBL14988269 0.94 MEN1 (0.65) MEN1ALDH1A1APPMAPTTHRB
SCHEMBL14988274 0.94 MEN1 (0.65) MEN1ALDH1A1APPMAPTTHRB
SCHEMBL15120182 0.93 MEN1 (0.67) MEN1ALDH1A1APPMAPTTHRB
SCHEMBL29697129 0.93 MEN1 (0.67) MEN1ALDH1A1APPMAPTTHRB
SCHEMBL18044255 0.93 MEN1 (0.67) MEN1ALDH1A1APPMAPTTHRB
SCHEMBL14988644 0.92 MEN1 (0.62) MEN1ALDH1A1APPMAPTTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9206129-B2 Agent for treatment of eye diseases DAITO CHEMIX CORPORATION (JP) 2015-12-08 — — US claimed
EP-3042658-B1 MEDICINAL COMPOSITION IMPROVING LEPTIN RESISTANCE UNIV KYOTO (JP) 2019-01-16 — — EP disclosed
EP-2959903-B1 MEDICINE FOR TREATING EYE DISEASE UNIV KYOTO (JP) 2018-10-03 — — EP disclosed
US-9931351-B2 Method for improving leptin resistance KYOTO UNIVERSITY (JP) 2018-04-03 — — US disclosed
US-9782420-B2 Method for treating eye diseases KYOTO UNIVERSITY (JP) 2017-10-10 — — US disclosed
US-9573887-B2 Naphthalene derivative DAITO CHEMIX CORPORATION (JP) 2017-02-21 — — US disclosed
US-20160303144-A1 Medicinal Composition Improving Leptin Resistance KYOTO UNIVERSITY (JP) 2016-10-20 — — US disclosed
EP-2599771-B1 NAPHTHALENE DERIVATIVE DAITO CHEMIX CORP (JP) 2016-09-14 — — EP disclosed
EP-3042658-A1 MEDICINAL COMPOSITION IMPROVING LEPTIN RESISTANCE Kyoto University (JP) 2016-07-13 — — EP disclosed
US-20160000810-A1 Method For Treating Eye Diseases KYOTO UNIVERSITY (JP) 2016-01-07 — — US disclosed
EP-2959903-A1 MEDICINE FOR TREATING EYE DISEASE Kyoto University (JP) 2015-12-30 — — EP disclosed
US-9206129-B2 Agent for treatment of eye diseases DAITO CHEMIX CORPORATION (JP) 2015-12-08 — — US disclosed
EP-2623494-B1 AGENT FOR TREATMENT OF EYE DISEASES DAITO CHEMIX CORP (JP) 2015-09-02 — — EP disclosed
US-20140148416-A1 Agent for Treatment of Eye Diseases KYOTO UNIVERSITY (JP) 2014-05-29 — — US disclosed
EP-2623494-A1 AGENT FOR TREATMENT OF EYE DISEASES Daito Chemix Corporation (JP) 2013-08-07 — — EP disclosed
US-20130184241-A1 Naphthalene Derivative KYOTO UNIVERSITY (JP) 2013-07-18 — — US disclosed
EP-2599771-A1 NAPHTHALENE DERIVATIVE Daito Chemix Corporation (JP) 2013-06-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160000810-A1 Method For Treating Eye Diseases CFB, AGER, CFH MEN1 4564/4885ALDH1A1 564/4885APP 807/4885
US-20140148416-A1 Agent for Treatment of Eye Diseases PDE6A, ALDH1A2, PDE6D MEN1 2216/4885ALDH1A1 695/4885APP 2255/4885
US-20160303144-A1 Medicinal Composition Improving Leptin Resistance LIPC, ADIPOR1, GPR119 MEN1 1433/4885ALDH1A1 574/4885APP 757/4885
US-20130184241-A1 Naphthalene Derivative VCP, NOC2L, VAT1 MEN1 2693/4885ALDH1A1 1402/4885APP 237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback